Table 1 Characteristics of all NET patients included in this study for Lu-177-Octreotate therapy
Octreotate | P1 | P2 | P3 | P4 | P5 |
|---|---|---|---|---|---|
Sex | M | M | F | F | F |
Age | 68 | 66 | 61 | 47 | 73 |
Activity investigated cycle [MBq] | 7654 | 7425 | 7420 | 7409 | 7410 |
Diagnosis | NET small intestine | NET | NET terminal ileum | NET pancreas | NET stomach |
Metastases (PET/CT) | |||||
- Extend | Medium | Medium | Medium | Medium | Medium |
- Type (VIS = visceral, LYM = lymph, OSS = osseous) | Mainly VIS (liver), LYM | Mainly LYM, VIS (liver) | Mainly VIS (liver), LYM, OSS | Mainly LYM, VIS (liver and other) | Mainly VIS (liver), OSS |
Proliferation index | Ki67 3–4% | Ki67 5–10% | Ki67 1% | Ki67 10% | Ki67 10% |
Pre-therapies | SSA-analogues | Interferon alpha | Hemicolectomy, SSA-analogues, radioembolization | Chemotherapy (stroptozotocin/5-FU, dacarbazapin, capecitabin/Te-modal) | SSA-analogues, bisphosphonate therapy |
Blood pre-therapy | |||||
- Leukocytes [G/l] | 7.76 | 10.4 | 3.79 | 3.93 | 10.2 |
- Erythrocytes [T/l] | 4.58 | 4.50 | 4.43 | 3.73 | 4.42 |
- Thrombocytes [G/l] | 207 | 294 | 297 | 177 | 303 |
- Haematocrit | 0.421 | 0.442 | 0.373 | 0.341 | 0.399 |